Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Significant Growth in Short Interest

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) was the recipient of a significant growth in short interest during the month of December. As of December 30th, there was short interest totalling 2,990,000 shares, a growth of 12.4% from the December 15th total of 2,660,000 shares. Based on an average daily trading volume, of 331,500 shares, the days-to-cover ratio is presently 9.0 days. Approximately 5.8% of the shares of the company are short sold.

Analysts Set New Price Targets

Several research firms have commented on ACRS. The Goldman Sachs Group began coverage on shares of Aclaris Therapeutics in a report on Thursday, December 1st. They issued a “buy” rating and a $25.00 price target on the stock. StockNews.com began coverage on shares of Aclaris Therapeutics in a report on Wednesday, October 12th. They issued a “sell” rating on the stock. SVB Leerink reaffirmed an “outperform” rating on shares of Aclaris Therapeutics in a report on Tuesday, November 8th. BTIG Research began coverage on shares of Aclaris Therapeutics in a report on Thursday, October 6th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Aclaris Therapeutics in a report on Tuesday, December 13th. They issued a “buy” rating and a $29.00 price target on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Aclaris Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $28.67.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $16.65 on Friday. The firm has a 50-day simple moving average of $16.36 and a two-hundred day simple moving average of $16.02. The company has a market cap of $1.11 billion, a P/E ratio of -12.91 and a beta of 0.52. Aclaris Therapeutics has a fifty-two week low of $9.26 and a fifty-two week high of $18.96.

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.09. The business had revenue of $19.02 million during the quarter, compared to the consensus estimate of $1.61 million. Aclaris Therapeutics had a negative net margin of 349.26% and a negative return on equity of 39.41%. Equities research analysts forecast that Aclaris Therapeutics will post -1.39 EPS for the current year.

Insider Activity

In other news, insider Joseph Monahan sold 5,000 shares of the business’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $15.88, for a total transaction of $79,400.00. Following the sale, the insider now directly owns 96,386 shares of the company’s stock, valued at $1,530,609.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Aclaris Therapeutics news, Director Neal Walker sold 25,000 shares of the company’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $15.25, for a total value of $381,250.00. Following the sale, the director now directly owns 1,220,763 shares of the company’s stock, valued at $18,616,635.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Joseph Monahan sold 5,000 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $15.88, for a total transaction of $79,400.00. Following the completion of the sale, the insider now directly owns 96,386 shares in the company, valued at $1,530,609.68. The disclosure for this sale can be found here. Insiders have sold 59,156 shares of company stock valued at $956,448 over the last ninety days. 6.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC acquired a new position in shares of Aclaris Therapeutics during the 2nd quarter worth about $26,000. Great West Life Assurance Co. Can acquired a new position in shares of Aclaris Therapeutics during the 3rd quarter worth about $31,000. UBS Group AG raised its position in shares of Aclaris Therapeutics by 41.4% during the 2nd quarter. UBS Group AG now owns 2,406 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 704 shares during the last quarter. Amalgamated Bank acquired a new position in shares of Aclaris Therapeutics during the 1st quarter worth about $143,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of Aclaris Therapeutics by 163.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,050 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 5,621 shares during the last quarter. Institutional investors and hedge funds own 95.33% of the company’s stock.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Articles

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.